Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 13/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 13/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.44 |
| ▸ | CDK2 | P24941 | 10/20 | 0.44 |
| ▸ | CDK7 | P50613 | 10/20 | 0.44 |
| ▸ | CCNH | P51946 | 10/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 10/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25216702 | 1.00 | CCNK (0.49) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL30533844 | 1.00 | CCNK (0.49) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL30533851 | 1.00 | CCNK (0.49) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL25233481 | 1.00 | CCNK (0.49) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL25221183 | 0.88 | CCNK (0.44) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL30464490 | 0.88 | CCNK (0.44) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL25268712 | 0.88 | CCNK (0.44) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL30464385 | 0.88 | CCNK (0.44) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL25273470 | 0.86 | CCNK (0.57) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL25273469 | 0.86 | CCNK (0.57) | CCNKCDK12CCNA2CDK2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | claimed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | CCNK 17/4885CDK12 1/4885CCNA2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.